XML 89 R78.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 10,465 | $ 9,930 | $ 20,502 | $ 19,365
Proceeds from sale of marketing rights |  |  | 71 | 50
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10,428 | 9,815 | 20,496 | 19,033
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 37 | 115 | 6 | 332
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,243 | 4,308 | 8,376 | 8,503
United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,189 | 4,300 | 8,296 | 8,437
United States | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 8 | 80 | 66
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,222 | 5,623 | 12,126 | 10,862
International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,240 | 5,515 | 12,200 | 10,596
International | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (18) | 108 | (74) | 266
Total Pharmaceutical segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 9,282 | 8,759 | 18,201 | 16,944
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,667 | 881 | 3,131 | 1,465
Total Pharmaceutical segment sales | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 148 | 143 | 273 | 276
Total Pharmaceutical segment sales | Operating Segments | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 65 | 113 | 130
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 44 | 0 | 76 | 0
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 0 | 35 | 0
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 608 | 469 | 1,269 | 1,001
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 426 | 399 | 818 | 754
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 193 | 166 | 372 | 329
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 156 | 123 | 349 | 347
Total Pharmaceutical segment sales | Operating Segments | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 44 | 160 | 108 | 313
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 240 | 163 | 444 | 310
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 188 | 155 | 363 | 296
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 149 | 150 | 300 | 286
Total Pharmaceutical segment sales | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 94 | 103 | 192 | 198
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 87 | 112 | 178 | 233
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 71 | 140 | 133
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 233 | 199 | 464 | 383
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 157 | 208 | 324 | 437
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 52 | 125 | 94
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 305 | 282 | 586 | 587
Total Pharmaceutical segment sales | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 113 | 517 | 243 | 895
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 226 | 367 | 531 | 701
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 155 | 182 | 322 | 423
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 101 | 63 | 174 | 112
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 67 | 143 | 151
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 949 | 948 | 1,829 | 1,787
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 585 | 563 | 1,129 | 1,059
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 236 | 199 | 452 | 359
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 174 | 178 | 348 | 349
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 185 | 203 | 360 | 389
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 125 | 119 | 245 | 231
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 81 | 85 | 203 | 224
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 84 | 89 | 166 | 192
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 79 | 138 | 160
Total Pharmaceutical segment sales | Operating Segments | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 59 | 66 | 114 | 127
Total Pharmaceutical segment sales | Operating Segments | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 69 | 99 | 151
Total Pharmaceutical segment sales | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,053 | 1,064 | 2,045 | 2,062
Total Pharmaceutical segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3,822 | 3,929 | 7,538 | 7,690
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 959 | 556 | 1,797 | 917
Total Pharmaceutical segment sales | United States | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 89 | 83 | 168 | 169
Total Pharmaceutical segment sales | United States | Operating Segments | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 3 | 2 | 4
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 31 | 0 | 55 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 302 | 312 | 682 | 711
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 356 | 341 | 668 | 639
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 122 | 104 | 234 | 219
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 99 | 72 | 250 | 251
Total Pharmaceutical segment sales | United States | Operating Segments | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 107 | 17 | 216
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 95 | 54 | 175 | 99
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 87 | 77 | 168 | 142
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 87 | 93 | 177 | 175
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 53 | 95 | 107
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | 6 | 7 | 11
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 1 | 5 | 2
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 29 | 25 | 52 | 45
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 132 | 136 | 260 | 279
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (10) | 256 | (10) | 455
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8 | 122 | 25 | 233
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 30 | 11 | 120
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 503 | 541 | 968 | 1,048
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 209 | 248 | 401 | 442
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 187 | 153 | 357 | 265
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 114 | 125 | 242 | 257
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5 | 6 | 11 | 12
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7 | 3 | 14 | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 21 | 2 | 39
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 27 | 32 | 56 | 74
Total Pharmaceutical segment sales | United States | Operating Segments | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 2 | 1 | 3
Total Pharmaceutical segment sales | United States | Operating Segments | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 63 | 85 | 139
Total Pharmaceutical segment sales | United States | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 289 | 304 | 563 | 611
Total Pharmaceutical segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,461 | 4,830 | 10,663 | 9,255
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 707 | 325 | 1,333 | 547
Total Pharmaceutical segment sales | International | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 59 | 60 | 105 | 107
Total Pharmaceutical segment sales | International | Operating Segments | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 61 | 111 | 126
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 13 | 0 | 22 | 0
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 0 | 35 | 0
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 306 | 156 | 586 | 290
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 58 | 150 | 115
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 61 | 137 | 110
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 57 | 51 | 99 | 96
Total Pharmaceutical segment sales | International | Operating Segments | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 52 | 91 | 97
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 145 | 109 | 269 | 211
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 78 | 195 | 154
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 57 | 123 | 111
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 46 | 50 | 97 | 92
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 83 | 106 | 171 | 222
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 70 | 135 | 132
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 233 | 199 | 464 | 383
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 157 | 208 | 324 | 437
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 28 | 73 | 49
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 174 | 146 | 326 | 308
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 123 | 261 | 253 | 440
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 218 | 246 | 505 | 468
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 152 | 152 | 311 | 303
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 101 | 63 | 174 | 112
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 67 | 143 | 151
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 446 | 407 | 862 | 740
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 377 | 315 | 729 | 617
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 47 | 95 | 94
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 53 | 106 | 92
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 180 | 197 | 350 | 377
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 118 | 116 | 231 | 226
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 81 | 64 | 201 | 185
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 84 | 89 | 166 | 192
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 47 | 81 | 86
Total Pharmaceutical segment sales | International | Operating Segments | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 65 | 113 | 124
Total Pharmaceutical segment sales | International | Operating Segments | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7 | 5 | 14 | 12
Total Pharmaceutical segment sales | International | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 765 | 761 | 1,483 | 1,449
Total Animal Health segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,090 | 955 | 2,155 | 1,894
Total Animal Health segment sales | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 633 | 582 | 1,286 | 1,161
Total Animal Health segment sales | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 457 | 373 | 869 | 733
Total Animal Health segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 311 | 270 | 618 | 553
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 107 | 103 | 231 | 223
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 204 | 167 | 387 | 330
Total Animal Health segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 779 | 685 | 1,537 | 1,341
Total Animal Health segment sales | International | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 526 | 479 | 1,055 | 938
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 253 | 206 | 482 | 403
Other segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 101 | 140 | 195
Other segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 101 | 140 | 194
Other segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |